 Mark Boguniewicz
Concepts (537)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 163 | 2025 | 319 | 24.840 |
Why?
| | Antibodies, Monoclonal, Humanized | 21 | 2024 | 759 | 3.180 |
Why?
| | Eczema | 14 | 2023 | 67 | 3.090 |
Why?
| | Severity of Illness Index | 48 | 2025 | 2742 | 2.030 |
Why?
| | Skin | 34 | 2024 | 725 | 1.920 |
Why?
| | Biological Products | 3 | 2024 | 202 | 1.760 |
Why?
| | Tacrolimus | 20 | 2023 | 193 | 1.730 |
Why?
| | Pruritus | 16 | 2024 | 58 | 1.520 |
Why?
| | Antibodies, Monoclonal | 8 | 2024 | 1367 | 1.510 |
Why?
| | Dermatologic Agents | 14 | 2024 | 65 | 1.480 |
Why?
| | Quality of Life | 30 | 2025 | 2704 | 1.450 |
Why?
| | Staphylococcus aureus | 15 | 2024 | 438 | 1.420 |
Why?
| | Practice Guidelines as Topic | 11 | 2025 | 1501 | 1.380 |
Why?
| | Asthma | 17 | 2024 | 2230 | 1.340 |
Why?
| | Staphylococcal Skin Infections | 8 | 2018 | 35 | 1.330 |
Why?
| | Immunosuppressive Agents | 15 | 2024 | 853 | 1.280 |
Why?
| | Keratinocytes | 12 | 2024 | 242 | 1.080 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2024 | 51 | 1.060 |
Why?
| | Calcineurin Inhibitors | 14 | 2010 | 68 | 0.940 |
Why?
| | Double-Blind Method | 26 | 2025 | 1876 | 0.930 |
Why?
| | Kaposi Varicelliform Eruption | 12 | 2013 | 21 | 0.920 |
Why?
| | Humans | 182 | 2025 | 129650 | 0.900 |
Why?
| | Boron Compounds | 3 | 2018 | 22 | 0.740 |
Why?
| | Cytokines | 17 | 2024 | 2017 | 0.740 |
Why?
| | Immunoglobulin E | 18 | 2023 | 329 | 0.720 |
Why?
| | Emollients | 4 | 2018 | 10 | 0.710 |
Why?
| | Urticaria | 3 | 2008 | 37 | 0.710 |
Why?
| | Hypersensitivity | 3 | 2023 | 249 | 0.700 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2020 | 8 | 0.700 |
Why?
| | Adrenal Cortex Hormones | 11 | 2023 | 522 | 0.680 |
Why?
| | Intermediate Filament Proteins | 7 | 2018 | 57 | 0.680 |
Why?
| | Treatment Outcome | 32 | 2025 | 10230 | 0.670 |
Why?
| | Administration, Topical | 16 | 2020 | 145 | 0.670 |
Why?
| | Janus Kinase Inhibitors | 3 | 2025 | 25 | 0.670 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2018 | 215 | 0.650 |
Why?
| | Bandages | 3 | 2016 | 32 | 0.630 |
Why?
| | Allergy and Immunology | 2 | 2017 | 43 | 0.620 |
Why?
| | Dermatology | 3 | 2017 | 117 | 0.620 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 248 | 0.620 |
Why?
| | Expert Testimony | 1 | 2019 | 36 | 0.610 |
Why?
| | Anti-Inflammatory Agents | 11 | 2020 | 480 | 0.600 |
Why?
| | Skin Care | 4 | 2008 | 21 | 0.590 |
Why?
| | Antimicrobial Cationic Peptides | 6 | 2010 | 77 | 0.580 |
Why?
| | Interferon-gamma | 11 | 2013 | 770 | 0.580 |
Why?
| | Adult | 75 | 2024 | 35576 | 0.570 |
Why?
| | Biological Therapy | 1 | 2017 | 28 | 0.560 |
Why?
| | Food Hypersensitivity | 6 | 2024 | 176 | 0.560 |
Why?
| | Psoriasis | 12 | 2023 | 87 | 0.540 |
Why?
| | Occlusive Dressings | 1 | 2016 | 5 | 0.540 |
Why?
| | Interleukin-13 | 10 | 2023 | 147 | 0.530 |
Why?
| | Interleukin-4 | 9 | 2023 | 212 | 0.500 |
Why?
| | Herpes Simplex | 3 | 2013 | 93 | 0.500 |
Why?
| | Advisory Committees | 1 | 2017 | 216 | 0.490 |
Why?
| | Desensitization, Immunologic | 5 | 2024 | 90 | 0.470 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 374 | 0.470 |
Why?
| | Cost of Illness | 9 | 2018 | 278 | 0.470 |
Why?
| | Child, Preschool | 32 | 2025 | 10517 | 0.460 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 122 | 0.460 |
Why?
| | Epidermis | 3 | 2017 | 155 | 0.460 |
Why?
| | beta-Defensins | 8 | 2010 | 21 | 0.440 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 3 | 2018 | 9 | 0.440 |
Why?
| | Simplexvirus | 3 | 2011 | 80 | 0.430 |
Why?
| | Glycyrrhetinic Acid | 3 | 2008 | 7 | 0.430 |
Why?
| | Conjunctivitis | 3 | 2023 | 30 | 0.430 |
Why?
| | Th2 Cells | 6 | 2017 | 171 | 0.420 |
Why?
| | Child | 43 | 2024 | 20883 | 0.420 |
Why?
| | Autoimmune Diseases | 4 | 2018 | 426 | 0.420 |
Why?
| | Anti-Allergic Agents | 3 | 2014 | 45 | 0.420 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 390 | 0.410 |
Why?
| | Hypersensitivity, Immediate | 3 | 2019 | 43 | 0.410 |
Why?
| | Calcineurin | 5 | 2006 | 98 | 0.400 |
Why?
| | Consensus | 5 | 2024 | 616 | 0.390 |
Why?
| | Immunity, Innate | 6 | 2011 | 804 | 0.360 |
Why?
| | Adolescent | 36 | 2024 | 20393 | 0.360 |
Why?
| | Allergens | 7 | 2023 | 385 | 0.360 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 339 | 0.350 |
Why?
| | Administration, Cutaneous | 9 | 2024 | 124 | 0.350 |
Why?
| | Male | 56 | 2025 | 63681 | 0.340 |
Why?
| | Drug Approval | 3 | 2020 | 88 | 0.340 |
Why?
| | Ointments | 10 | 2016 | 24 | 0.340 |
Why?
| | Adaptive Immunity | 1 | 2011 | 161 | 0.340 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1004 | 0.330 |
Why?
| | Plant Extracts | 3 | 2008 | 199 | 0.330 |
Why?
| | Membrane Proteins | 5 | 2024 | 1119 | 0.320 |
Why?
| | Complementary Therapies | 1 | 2010 | 87 | 0.320 |
Why?
| | Dietary Fats | 2 | 2008 | 301 | 0.310 |
Why?
| | Disease Progression | 6 | 2019 | 2635 | 0.310 |
Why?
| | Infant | 23 | 2024 | 9024 | 0.310 |
Why?
| | Drug Hypersensitivity | 3 | 1995 | 81 | 0.310 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 221 | 0.310 |
Why?
| | Off-Label Use | 2 | 2020 | 51 | 0.310 |
Why?
| | Staphylococcal Infections | 4 | 2023 | 393 | 0.300 |
Why?
| | Receptors, IgE | 1 | 2008 | 44 | 0.300 |
Why?
| | Female | 54 | 2025 | 68776 | 0.300 |
Why?
| | Population Groups | 2 | 2018 | 60 | 0.300 |
Why?
| | Prevalence | 12 | 2019 | 2564 | 0.290 |
Why?
| | Inflammation | 4 | 2018 | 2736 | 0.290 |
Why?
| | Chronic Disease | 12 | 2019 | 1720 | 0.290 |
Why?
| | Disease Management | 5 | 2020 | 589 | 0.280 |
Why?
| | Self Report | 7 | 2019 | 799 | 0.280 |
Why?
| | United States | 20 | 2024 | 13903 | 0.280 |
Why?
| | Comorbidity | 6 | 2024 | 1547 | 0.270 |
Why?
| | Rhinitis, Allergic | 2 | 2024 | 38 | 0.260 |
Why?
| | Cross-Sectional Studies | 14 | 2021 | 5066 | 0.250 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 1717 | 0.250 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2025 | 4 | 0.240 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2016 | 70 | 0.240 |
Why?
| | Patch Tests | 3 | 2016 | 56 | 0.240 |
Why?
| | Vaccinia virus | 4 | 2011 | 42 | 0.240 |
Why?
| | Phototherapy | 3 | 2018 | 30 | 0.240 |
Why?
| | Middle Aged | 37 | 2024 | 31154 | 0.230 |
Why?
| | Omalizumab | 2 | 2020 | 50 | 0.230 |
Why?
| | Steroids | 3 | 2017 | 158 | 0.230 |
Why?
| | Exanthema | 1 | 2005 | 74 | 0.230 |
Why?
| | Aminopyridines | 1 | 2025 | 97 | 0.230 |
Why?
| | Diagnosis, Differential | 7 | 2008 | 1434 | 0.220 |
Why?
| | Benzamides | 1 | 2025 | 207 | 0.220 |
Why?
| | Ectropion | 1 | 2023 | 1 | 0.210 |
Why?
| | Janus Kinases | 1 | 2023 | 12 | 0.210 |
Why?
| | Anxiety | 3 | 2019 | 966 | 0.210 |
Why?
| | Blepharitis | 1 | 2023 | 5 | 0.210 |
Why?
| | Down-Regulation | 7 | 2017 | 636 | 0.210 |
Why?
| | Animals | 17 | 2024 | 35361 | 0.200 |
Why?
| | Sublingual Immunotherapy | 1 | 2022 | 6 | 0.200 |
Why?
| | Pain | 2 | 2019 | 789 | 0.200 |
Why?
| | Receptors, Interleukin | 3 | 2020 | 43 | 0.200 |
Why?
| | Pyrimidines | 2 | 2024 | 459 | 0.200 |
Why?
| | Tight Junctions | 3 | 2011 | 75 | 0.190 |
Why?
| | Sickness Impact Profile | 2 | 2019 | 55 | 0.190 |
Why?
| | Cefuroxime | 1 | 2001 | 4 | 0.190 |
Why?
| | Recurrence | 4 | 2019 | 1007 | 0.190 |
Why?
| | Drug Industry | 2 | 2018 | 106 | 0.190 |
Why?
| | Depression | 3 | 2019 | 1307 | 0.190 |
Why?
| | Cephalosporins | 1 | 2001 | 40 | 0.180 |
Why?
| | Pyrazoles | 1 | 2024 | 405 | 0.180 |
Why?
| | STAT6 Transcription Factor | 3 | 2011 | 26 | 0.180 |
Why?
| | Biomarkers | 7 | 2024 | 3973 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 5 | 2024 | 373 | 0.180 |
Why?
| | Patient Education as Topic | 5 | 2015 | 743 | 0.170 |
Why?
| | Autoantibodies | 1 | 2008 | 1466 | 0.170 |
Why?
| | Evidence-Based Medicine | 3 | 2024 | 718 | 0.170 |
Why?
| | Bacterial Toxins | 3 | 2012 | 106 | 0.170 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 152 | 0.160 |
Why?
| | Injections, Subcutaneous | 4 | 2023 | 147 | 0.160 |
Why?
| | Skin Diseases, Infectious | 3 | 2008 | 15 | 0.160 |
Why?
| | Vaccines | 1 | 2024 | 398 | 0.160 |
Why?
| | Patient Health Questionnaire | 1 | 2018 | 36 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 89 | 0.150 |
Why?
| | Sulfonamides | 1 | 2022 | 496 | 0.150 |
Why?
| | Drug Administration Schedule | 5 | 2025 | 769 | 0.150 |
Why?
| | Injections | 1 | 2019 | 174 | 0.150 |
Why?
| | Surveys and Questionnaires | 5 | 2019 | 5406 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2023 | 1368 | 0.140 |
Why?
| | Gene Expression Regulation | 7 | 2011 | 2548 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 252 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 6 | 2011 | 2282 | 0.140 |
Why?
| | Immunologic Factors | 2 | 2005 | 231 | 0.140 |
Why?
| | Guidelines as Topic | 2 | 2018 | 264 | 0.140 |
Why?
| | T-Lymphocytes | 6 | 2006 | 1928 | 0.140 |
Why?
| | Skin Diseases | 1 | 2019 | 143 | 0.140 |
Why?
| | Skin Diseases, Viral | 2 | 2018 | 5 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1266 | 0.130 |
Why?
| | Gloves, Surgical | 1 | 1996 | 3 | 0.130 |
Why?
| | Gloves, Protective | 1 | 1996 | 2 | 0.130 |
Why?
| | Latex | 1 | 1996 | 9 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2018 | 200 | 0.130 |
Why?
| | Rubber | 1 | 1996 | 6 | 0.130 |
Why?
| | Cells, Cultured | 13 | 2011 | 4083 | 0.130 |
Why?
| | Dermatitis, Occupational | 1 | 1996 | 14 | 0.130 |
Why?
| | Bronchial Hyperreactivity | 1 | 1996 | 105 | 0.120 |
Why?
| | Histamine H1 Antagonists | 2 | 2006 | 29 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 2 | 2019 | 759 | 0.120 |
Why?
| | Chemokines, CC | 3 | 2006 | 33 | 0.120 |
Why?
| | Receptors, Cytokine | 2 | 2010 | 35 | 0.120 |
Why?
| | Milk Proteins | 1 | 2015 | 33 | 0.120 |
Why?
| | Skin Cream | 2 | 2025 | 12 | 0.120 |
Why?
| | Milk Hypersensitivity | 1 | 2015 | 19 | 0.120 |
Why?
| | Primary Health Care | 2 | 2016 | 1680 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 412 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 303 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2019 | 504 | 0.120 |
Why?
| | Young Adult | 11 | 2024 | 12426 | 0.120 |
Why?
| | Hydrotherapy | 1 | 2014 | 8 | 0.110 |
Why?
| | Infant Formula | 1 | 2015 | 74 | 0.110 |
Why?
| | Patient Care Planning | 1 | 2015 | 149 | 0.110 |
Why?
| | Patient-Centered Care | 2 | 2018 | 505 | 0.110 |
Why?
| | Skin Tests | 3 | 2012 | 100 | 0.110 |
Why?
| | Gene Expression Profiling | 4 | 2011 | 1706 | 0.110 |
Why?
| | Algorithms | 3 | 2018 | 1622 | 0.110 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.110 |
Why?
| | Network Meta-Analysis | 2 | 2023 | 9 | 0.110 |
Why?
| | Recombinant Proteins | 6 | 2006 | 1304 | 0.110 |
Why?
| | Risk Factors | 8 | 2015 | 9765 | 0.110 |
Why?
| | Lipids | 1 | 2017 | 625 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2020 | 2012 | 0.110 |
Why?
| | Health Status | 1 | 2018 | 755 | 0.100 |
Why?
| | Delphi Technique | 2 | 2024 | 225 | 0.100 |
Why?
| | RNA, Messenger | 10 | 2007 | 2708 | 0.100 |
Why?
| | Cholecalciferol | 1 | 2013 | 56 | 0.100 |
Why?
| | Aged | 13 | 2019 | 22103 | 0.100 |
Why?
| | Logistic Models | 4 | 2019 | 1988 | 0.100 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 4 | 0.100 |
Why?
| | Vitamins | 1 | 2013 | 174 | 0.090 |
Why?
| | Fibronectins | 2 | 2023 | 123 | 0.090 |
Why?
| | Research Design | 1 | 2018 | 1044 | 0.090 |
Why?
| | Immunity, Cellular | 1 | 2013 | 265 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 292 | 0.090 |
Why?
| | Vitamin D | 2 | 2013 | 384 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2011 | 2119 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2011 | 2073 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 526 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 2 | 2008 | 11 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2010 | 1056 | 0.090 |
Why?
| | Signal Transduction | 2 | 2023 | 4925 | 0.090 |
Why?
| | Th1-Th2 Balance | 1 | 2010 | 8 | 0.090 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 161 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 575 | 0.090 |
Why?
| | Histamine Antagonists | 1 | 2010 | 20 | 0.090 |
Why?
| | Receptors, Chemokine | 1 | 2010 | 45 | 0.090 |
Why?
| | Chickenpox Vaccine | 1 | 2010 | 71 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 27 | 0.090 |
Why?
| | Therapies, Investigational | 1 | 2010 | 17 | 0.090 |
Why?
| | Cathelicidins | 5 | 2010 | 37 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2010 | 141 | 0.080 |
Why?
| | Genetic Variation | 2 | 2011 | 937 | 0.080 |
Why?
| | Cardiovascular Diseases | 2 | 2018 | 2004 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1242 | 0.080 |
Why?
| | Adjuvants, Immunologic | 3 | 2004 | 221 | 0.080 |
Why?
| | Mice | 9 | 2012 | 16937 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3144 | 0.080 |
Why?
| | Pediatrics | 2 | 2015 | 1052 | 0.080 |
Why?
| | Coal Tar | 1 | 2008 | 3 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1040 | 0.080 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 534 | 0.080 |
Why?
| | Disease Outbreaks | 1 | 2012 | 349 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 769 | 0.080 |
Why?
| | Cell Degranulation | 1 | 2008 | 42 | 0.080 |
Why?
| | Pyroglyphidae | 2 | 2022 | 17 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2019 | 7086 | 0.070 |
Why?
| | Irritants | 1 | 2008 | 48 | 0.070 |
Why?
| | Basophils | 1 | 2008 | 73 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.070 |
Why?
| | Dosage Forms | 1 | 2008 | 12 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 640 | 0.070 |
Why?
| | United Kingdom | 2 | 2019 | 257 | 0.070 |
Why?
| | Environmental Exposure | 1 | 2012 | 462 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1902 | 0.070 |
Why?
| | Phenotype | 4 | 2023 | 3076 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2011 | 1198 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1103 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2014 | 1206 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 857 | 0.070 |
Why?
| | Mast Cells | 1 | 2008 | 142 | 0.070 |
Why?
| | Reference Values | 2 | 2019 | 793 | 0.070 |
Why?
| | Clinical Protocols | 1 | 2008 | 255 | 0.070 |
Why?
| | Protein Precursors | 1 | 2007 | 127 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2010 | 331 | 0.070 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2006 | 11 | 0.070 |
Why?
| | Drug Combinations | 3 | 2020 | 330 | 0.070 |
Why?
| | Patient Dropouts | 1 | 2007 | 64 | 0.070 |
Why?
| | Immunohistochemistry | 6 | 2010 | 1698 | 0.070 |
Why?
| | Cost-Benefit Analysis | 3 | 2018 | 569 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 333 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 66 | 0.070 |
Why?
| | Virus Replication | 2 | 2006 | 451 | 0.060 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1106 | 0.060 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 2006 | 16 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2006 | 57 | 0.060 |
Why?
| | Proteins | 2 | 2010 | 942 | 0.060 |
Why?
| | Gene Frequency | 3 | 2013 | 503 | 0.060 |
Why?
| | Immunoglobulins | 2 | 2005 | 159 | 0.060 |
Why?
| | Thiazoles | 1 | 2006 | 117 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2025 | 89 | 0.060 |
Why?
| | Thyroid Diseases | 1 | 2005 | 35 | 0.060 |
Why?
| | Models, Immunological | 1 | 2005 | 95 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2004 | 49 | 0.060 |
Why?
| | Interleukins | 1 | 2006 | 241 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2023 | 847 | 0.060 |
Why?
| | Resorcinols | 1 | 2023 | 5 | 0.060 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 214 | 0.050 |
Why?
| | Stilbenes | 1 | 2023 | 36 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | Lactams | 2 | 1995 | 21 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2019 | 422 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2023 | 24 | 0.050 |
Why?
| | Gene Expression | 4 | 2007 | 1472 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 14 | 0.050 |
Why?
| | Acute Disease | 6 | 2008 | 980 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 304 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2003 | 9 | 0.050 |
Why?
| | Leukocyte Count | 2 | 1995 | 326 | 0.050 |
Why?
| | Patient Care Team | 1 | 2008 | 605 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 474 | 0.050 |
Why?
| | Risk | 2 | 2018 | 854 | 0.050 |
Why?
| | Prednisone | 2 | 1994 | 233 | 0.050 |
Why?
| | Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
| | Patient Compliance | 1 | 2007 | 565 | 0.050 |
Why?
| | Conflict of Interest | 1 | 2004 | 123 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2003 | 108 | 0.050 |
Why?
| | Granuloma, Respiratory Tract | 1 | 2002 | 11 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 3794 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 72 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2023 | 118 | 0.050 |
Why?
| | Insurance, Physician Services | 1 | 2002 | 4 | 0.050 |
Why?
| | Caregivers | 2 | 2023 | 815 | 0.050 |
Why?
| | Baths | 1 | 2022 | 15 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 93 | 0.050 |
Why?
| | Lymphoma | 2 | 2018 | 196 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 545 | 0.050 |
Why?
| | Langerhans Cells | 1 | 2001 | 11 | 0.050 |
Why?
| | 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 11 | 0.050 |
Why?
| | Prospective Studies | 2 | 2020 | 7133 | 0.050 |
Why?
| | North America | 1 | 2022 | 291 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 592 | 0.050 |
Why?
| | Superantigens | 1 | 2001 | 70 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 112 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2002 | 82 | 0.050 |
Why?
| | Eosinophils | 2 | 1995 | 324 | 0.050 |
Why?
| | Time Factors | 2 | 2007 | 6556 | 0.050 |
Why?
| | Prodrugs | 1 | 2001 | 48 | 0.050 |
Why?
| | Claudin-1 | 2 | 2011 | 21 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2001 | 119 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4063 | 0.040 |
Why?
| | Beryllium | 1 | 2002 | 152 | 0.040 |
Why?
| | Bacterial Adhesion | 1 | 2001 | 91 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2717 | 0.040 |
Why?
| | Placebos | 1 | 2021 | 201 | 0.040 |
Why?
| | Diet | 2 | 2022 | 1213 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 375 | 0.040 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.040 |
Why?
| | Fibrinogen | 1 | 2001 | 164 | 0.040 |
Why?
| | Health Expenditures | 1 | 2002 | 179 | 0.040 |
Why?
| | Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 833 | 0.040 |
Why?
| | Markov Chains | 2 | 2015 | 117 | 0.040 |
Why?
| | Chemokines, CXC | 2 | 2003 | 70 | 0.040 |
Why?
| | Leg Dermatoses | 1 | 2019 | 1 | 0.040 |
Why?
| | Scalp Dermatoses | 1 | 2019 | 2 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3240 | 0.040 |
Why?
| | Foot Dermatoses | 1 | 2019 | 4 | 0.040 |
Why?
| | Buttocks | 1 | 2019 | 12 | 0.040 |
Why?
| | Hand Dermatoses | 1 | 2019 | 7 | 0.040 |
Why?
| | Facial Dermatoses | 1 | 2019 | 16 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 427 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2002 | 644 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 140 | 0.040 |
Why?
| | Genitalia | 1 | 2019 | 30 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 2011 | 23 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2011 | 360 | 0.040 |
Why?
| | Biopsy | 4 | 2007 | 1097 | 0.040 |
Why?
| | Torso | 1 | 2019 | 31 | 0.040 |
Why?
| | Haplotypes | 2 | 2011 | 475 | 0.040 |
Why?
| | Interleukin-16 | 1 | 1998 | 6 | 0.040 |
Why?
| | Autoantigens | 1 | 2001 | 417 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 169 | 0.040 |
Why?
| | Skin Diseases, Bacterial | 1 | 2018 | 21 | 0.040 |
Why?
| | Association | 1 | 2018 | 12 | 0.040 |
Why?
| | Canada | 1 | 2020 | 350 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 32 | 0.040 |
Why?
| | Acetamides | 1 | 2018 | 36 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2018 | 31 | 0.040 |
Why?
| | Arm | 1 | 2019 | 107 | 0.040 |
Why?
| | Phthalic Acids | 1 | 2018 | 46 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 118 | 0.040 |
Why?
| | Herpesvirus 2, Human | 2 | 2009 | 28 | 0.040 |
Why?
| | Age Distribution | 1 | 2018 | 372 | 0.040 |
Why?
| | Medicaid | 1 | 2002 | 433 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 359 | 0.040 |
Why?
| | Fundoplication | 1 | 1997 | 54 | 0.030 |
Why?
| | Pilot Projects | 2 | 1995 | 1587 | 0.030 |
Why?
| | Immune System | 1 | 2018 | 175 | 0.030 |
Why?
| | Quinazolines | 1 | 2018 | 244 | 0.030 |
Why?
| | Peak Expiratory Flow Rate | 2 | 1993 | 36 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 204 | 0.030 |
Why?
| | Monocytes | 2 | 2002 | 551 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2019 | 529 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 470 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1062 | 0.030 |
Why?
| | Texas | 2 | 2008 | 229 | 0.030 |
Why?
| | Forced Expiratory Volume | 2 | 1997 | 510 | 0.030 |
Why?
| | Health Occupations | 1 | 1996 | 30 | 0.030 |
Why?
| | Interleukin-12 | 1 | 1996 | 118 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1996 | 299 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1348 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 691 | 0.030 |
Why?
| | Whey Proteins | 1 | 2015 | 4 | 0.030 |
Why?
| | Penicillins | 1 | 1995 | 57 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 958 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 1997 | 232 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 478 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 685 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1502 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 868 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1996 | 131 | 0.030 |
Why?
| | Legionellosis | 1 | 1994 | 2 | 0.030 |
Why?
| | Legionnaires' Disease | 1 | 1994 | 4 | 0.030 |
Why?
| | Dermatitis, Irritant | 2 | 2004 | 10 | 0.030 |
Why?
| | Anaphylaxis | 1 | 1996 | 98 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2010 | 1038 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 1995 | 83 | 0.030 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 398 | 0.030 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 35 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 92 | 0.030 |
Why?
| | Milk | 1 | 2015 | 120 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1214 | 0.030 |
Why?
| | Cohort Studies | 2 | 2015 | 5420 | 0.030 |
Why?
| | Methylprednisolone | 1 | 1994 | 83 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 147 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 503 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 355 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 1993 | 30 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1996 | 349 | 0.030 |
Why?
| | Chemokine CXCL10 | 2 | 2009 | 34 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3381 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 186 | 0.030 |
Why?
| | Laparoscopy | 1 | 1997 | 451 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1968 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2006 | 1245 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1839 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2019 | 578 | 0.020 |
Why?
| | Chemokines | 2 | 2006 | 226 | 0.020 |
Why?
| | Cockroaches | 1 | 2012 | 20 | 0.020 |
Why?
| | Respiratory System | 1 | 1993 | 154 | 0.020 |
Why?
| | Treatment Failure | 1 | 1993 | 340 | 0.020 |
Why?
| | Haptens | 1 | 1992 | 20 | 0.020 |
Why?
| | Patient Care | 1 | 2013 | 109 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3083 | 0.020 |
Why?
| | Cats | 1 | 2012 | 208 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 2871 | 0.020 |
Why?
| | Vaccinia | 1 | 2011 | 21 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 547 | 0.020 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1991 | 28 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 381 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 50 | 0.020 |
Why?
| | Lung Diseases | 1 | 1997 | 742 | 0.020 |
Why?
| | Family | 1 | 2015 | 657 | 0.020 |
Why?
| | Microbiota | 1 | 2019 | 730 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 376 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1952 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2010 | 178 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2781 | 0.020 |
Why?
| | Health Care Costs | 2 | 2003 | 367 | 0.020 |
Why?
| | Chemokine CCL27 | 1 | 2009 | 1 | 0.020 |
Why?
| | Chemokine CCL17 | 1 | 2009 | 5 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2644 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3717 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2070 | 0.020 |
Why?
| | Lung | 1 | 2002 | 3930 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 387 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 496 | 0.020 |
Why?
| | Interferon-beta | 1 | 2009 | 89 | 0.020 |
Why?
| | Skin Physiological Phenomena | 1 | 2008 | 24 | 0.020 |
Why?
| | Herpesvirus 1, Human | 1 | 2009 | 86 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 117 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 13 | 0.020 |
Why?
| | Fluticasone | 1 | 2007 | 90 | 0.020 |
Why?
| | Chemokine CCL20 | 1 | 2006 | 5 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 1998 | 295 | 0.020 |
Why?
| | Androstadienes | 1 | 2007 | 106 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 652 | 0.020 |
Why?
| | Thiazolidines | 1 | 2006 | 9 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2006 | 27 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 88 | 0.020 |
Why?
| | Vitis | 1 | 2006 | 41 | 0.020 |
Why?
| | Apoptosis | 1 | 1995 | 2503 | 0.020 |
Why?
| | Europe | 1 | 2006 | 364 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2883 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2009 | 601 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1288 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2005 | 62 | 0.010 |
Why?
| | Erythema | 1 | 2004 | 28 | 0.010 |
Why?
| | Genomics | 1 | 2010 | 716 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2005 | 171 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 64 | 0.010 |
Why?
| | DNA, Viral | 1 | 2006 | 350 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 5762 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 505 | 0.010 |
Why?
| | Collagen Type III | 1 | 2003 | 14 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5500 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2006 | 309 | 0.010 |
Why?
| | Retreatment | 1 | 2003 | 70 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2006 | 478 | 0.010 |
Why?
| | Collagen Type I | 1 | 2003 | 119 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 21 | 0.010 |
Why?
| | Societies, Medical | 1 | 2006 | 751 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 157 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2142 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 786 | 0.010 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2003 | 94 | 0.010 |
Why?
| | Immunoblotting | 1 | 2002 | 305 | 0.010 |
Why?
| | Health Services | 1 | 2003 | 99 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2003 | 311 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1213 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2004 | 433 | 0.010 |
Why?
| | Chemotactic Factors, Eosinophil | 1 | 2000 | 7 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 457 | 0.010 |
Why?
| | Chemokine CCL11 | 1 | 2000 | 26 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 840 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1902 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2004 | 634 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2001 | 173 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2001 | 144 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 336 | 0.010 |
Why?
| | Odds Ratio | 1 | 2003 | 1023 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 248 | 0.010 |
Why?
| | Receptors, Interleukin-12 | 1 | 1998 | 7 | 0.010 |
Why?
| | Receptors, Interleukin-5 | 1 | 1998 | 6 | 0.010 |
Why?
| | Receptors, Interleukin-4 | 1 | 1998 | 15 | 0.010 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 15 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2058 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1156 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 945 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2832 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 14518 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1722 | 0.010 |
Why?
| | Colorado | 1 | 2006 | 4421 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1997 | 586 | 0.010 |
Why?
| | Immunocompetence | 1 | 1994 | 44 | 0.010 |
Why?
| | Interleukin-5 | 1 | 1994 | 45 | 0.010 |
Why?
| | Methacholine Chloride | 1 | 1993 | 51 | 0.010 |
Why?
| | Bronchial Provocation Tests | 1 | 1993 | 51 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1994 | 300 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 170 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1993 | 262 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1993 | 189 | 0.010 |
Why?
| | Bronchi | 1 | 1993 | 247 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1993 | 666 | 0.010 |
Why?
| | Cell Survival | 1 | 1995 | 1086 | 0.010 |
Why?
| | Enterotoxins | 1 | 1991 | 89 | 0.010 |
Why?
| | Neoplasms | 1 | 2005 | 2470 | 0.010 |
Why?
| | Macrophages, Alveolar | 1 | 1993 | 389 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1991 | 137 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1991 | 130 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1993 | 958 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1993 | 1418 | 0.000 |
Why?
|
|
Boguniewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|